Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of XZP-5610 in Healthy Subjects
NCT04913090Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XZP-5610 in Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 14, Time to Maximum Plasma Concentration at Day 14 and 3 more. Status: unknown.
02
Drugs
XZP-5610
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04913090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913090.